Autres langues

27/09/23 Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)
11/02/23 Tetra Bio-Pharma Announces Listing to OTCPink Market
22/12/22 REDUVO™ Marketing Approval on the Right Path
06/12/22 Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
29/11/22 Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
27/10/22 Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean
06/09/22 Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
10/08/22 Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections
30/05/22 Tetra Bio-Pharma Appoints Chief Financial Officer
16/02/22 Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec
14/02/22 Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna
29/11/21 QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
05/11/21 Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
21/10/21 Tetra Bio Pharma : Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency
05/10/21 Tetra Bio Pharma : REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
19/12/19 Tetra Bio-Pharma CEO, Dr. Guy Chamberland, Is Featured on the Stock Day Podcast
Aucun résultat pour cette recherche